Objective: Levels of serum albumin have recently emerged, together with C-reactive protein, as an important prognostic indicator for hepatocellular carcinoma (HCC). It has recently been reported that larger HCCs are associated with lower albumin levels. However, the albumin-mediated growth decrease has yet to be determined. Methods: We examined a large HCC cohort and then by direct exposure of HCC cells in vitro, the relationship of albumin levels to HCC growth. Results: We found that patients with lower albumin levels had significantly larger maximum tumor diameters, more portal vein thrombosis, more tumor multifocality, higher α-fetoprotein levels, and a lower survival than patients with higher albumin levels. Direct addition of exogenous albumin at physiological concentrations resulted in decreased growth in several HCC cell lines in vitro. We found a decrease in MAP kinase levels and in levels of Cdk2 and Cdk4, cyclinE, as well as in α-fetoprotein. Conclusion: These results indicate that in addition to its role as a monitor of systemic inflammation, albumin may have a direct role in HCC growth inhibition, either through modulation of α-fetoprotein or through its actions on growth-controlling kinases.

Keywords:
Hepatocellular carcinoma, Growth inhibition, Prognosis, Albumin
1.
Llado L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, Torras J, Fabregat J, Guardiola J, Jaurrieta E: A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000;88:50-57.
2.
Carr BI, Pancoska P, Branch RA: Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int 2009;4:396-405.
3.
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003;89:1028-1030.
4.
Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS: Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer 2004;90:1707-1709.
5.
Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Sattar N: Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer 2004;48:171-173.
6.
Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T: Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma. J Surg Oncol 2011;103:801-806.
7.
Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T: Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg 2012;203:101-106.
8.
Horino K, Beppu T, Kuroki H, Mima K, Okabe H, Nakahara O, Ikuta Y, Chikamoto A, Ishiko T, Takamori H, Baba H: Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma. Int J Clin Oncol 2013;18:829-838.
9.
Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Saeki C, Tajiri H: The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 2013;13:52.
10.
Li MX, Bi XY, Li ZY, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao H, Cai JQ: Prognostic role of Glasgow Prognostic Score in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Medicine (Baltimore) 2015;94:e2133.
11.
Carr BI, Guerra V, Gianinni EG, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Benvegnu L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F: An HCC aggressiveness index and blood GGTP, bilirubin and platelet levels. J Integr Oncol 2016;5:2.
12.
Carr BI, Lin CY, Lu SN: Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol 2014;41:415-421.
13.
Carr BI, Guerra V: A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology 2016;90:215-220.
14.
Bozkaya G, Korhan P, Cokakli M, Erdal E, Sagol O, Karademir S, Korch C, Atabey N: Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis. Mol Cancer 2012;11:64.
15.
Laursen I, Briand P, Lykkesfeldt AE: Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res 1990;10:343-351.
16.
Nojiri S, Joh T: Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci 2014;15:5163-5174.
17.
Nojiri S, Kusakabe A, Shinkai N, Matsuura K, Iio E, Miyaki T, Joh T: Factors influencing distant recurrence of hepatocellular carcinoma following combined radiofrequency ablation and transarterial chemoembolization therapy in patients with hepatitis C. Cancer Manag Res 2011;3:267-272.
18.
Wu GX, Lin YM, Zhou TH, Gao H, Pei G: Significant down-regulation of alpha-albumin in human hepatoma and its implication. Cancer Lett 2000;160:229-236.
19.
Ljubimova JY, Petrovic LM, Wilson SE, Geller SA, Demetriou AA: Expression of HGF, its receptor c-met, c-myc, and albumin in cirrhotic and neoplastic human liver tissue. J Histochem Cytochem 1997;45:79-87.
20.
Wong IH, Lau WY, Leung T, Johnson PJ: Quantitative comparison of alpha-fetoprotein and albumin mRNA levels in hepatocellular carcinoma/adenoma, non-tumor liver and blood: implications in cancer detection and monitoring. Cancer Lett 2000;156:141-149.
21.
Nayak NC, Mital I: The dynamics of alpha-fetoprotein and albumin synthesis in human and rat liver during normal ontogeny. Am J Pathol 1977;86:359-374.
22.
Esumi H, Takahashi Y, Seki M, Sato S, Nagase S, Sugimura T: Perinatal changes of alpha-fetoprotein concentration in the serum and its synthesis in the liver of analbuminemic rats. Cancer Res 1982;42:306-308.
23.
Kojiro M, Kawano Y, Isomura T, Nakashima T: Distribution of albumin- and/or alpha-fetoprotein-positive cells in hepatocellular carcinoma. Lab Invest 1981;44:221-226.
24.
Niwa Y, Matsumura M, Shiratori Y, Imamura M, Kato N, Shiina S, Okudaira T, Ikeda Y, Inoue T, Omata M: Quantitation of alpha-fetoprotein and albumin messenger RNA in human hepatocellular carcinoma. Hepatology 1996;23:1384-1392.
25.
Li H, Quan J, Zhang M, Yung BC, Cheng X, Liu Y, Lee YB, Ahn CH, Kim DJ, Lee RJ: Lipid-albumin nanoparticles (LAN) for therapeutic delivery of antisense oligonucleotide against HIF-1α. Mol Pharm 2016;13:2555-2562.
26.
Zheng K, Li R, Zhou X, Hu P, Zhang Y, Huang Y, Chen Z, Huang M: Dual actions of albumin packaging and tumor targeting enhance the antitumor efficacy and reduce the cardiotoxicity of doxorubicin in vivo. Int J Nanomedicine 2015;10:5327-5342.
27.
Dag A, Jiang Y, Karim KJ, Hart-Smith G, Scarano W, Stenzel MH: Polymer-albumin conjugate for the facilitated delivery of macromolecular platinum drugs. Macromol Rapid Commun 2015;36:890-897.
28.
Carr BI, Guerra V, Gianinni EG, Farinati F, Ciccarese F, Rapaccini GL, Marco MD, Benvegnu L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F: A liver index and its relationship to indices of HCC aggressiveness. J Integr Oncol 2016;5:3.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.